Table 3.
Pharmacodynamic parameters in COPD patients treated with V0162 versus placebo
| COPD patients | |||
|---|---|---|---|
| V0162 (n = 20) | Placebo (n = 20) | p-value | |
| FEV1 | |||
| AUC30min/6h, L | 1.36 ± 0.13 | 1.26 ± 0.11 | 0.004 |
| AUC30min/9h, L | 1.36 ± 0.12 | 1.26 ± 0.12 | 0.003 |
| AUC30min/22h, L | 1.33 ± 0.12 | 1.24 ± 0.12 | 0.006 |
| AUC30min/28h, L | 1.34 ± 0.12 | 1.25 ± 0.12 | 0.007 |
| AUC30min/32h, L | 1.35 ± 0.12 | 1.27 ± 0.12 | 0.006 |
| Trough FEV1, L | 1.19 ± 0.11 | 1.11 ± 0.11 | 0.016 |
| FVC | |||
| AUC30min/6h, L | 3.01 ± 0.20 | 2.86 ± 0.18 | 0.019 |
| AUC30min/9h, L | 3.01 ± 0.19 | 2.87 ± 0.19 | 0.011 |
| AUC30min/22h, L | 2.96 ± 0.18 | 2.83 ± 0.18 | 0.017 |
| AUC30min/28h, L | 2.96 ± 0.19 | 2.84 ± 0.18 | 0.013 |
| AUC30min/32h, L | 2.98 ± 0.19 | 2.85 ± 0.19 | 0.014 |
| FRC | |||
| AUC30min/6h, L | 5.24 ± 0.23 | 5.45 ± 0.29 | <0.001 |
| AUC30min/9h, L | 5.25 ± 0.25 | 5.51 ± 0.25 | <0.001 |
| AUC30min/22h, L | 5.34 ± 0.24 | 5.52 ± 0.24 | 0.006 |
| AUC30min/28h, L | 5.21 ± 0.24 | 5.43 ± 0.29 | 0.003 |
| AUC30min/32h, L | 5.22 ± 0.24 | 5.41 ± 0.29 | 0.003 |
| Dyspnea | |||
| nIAUC30min/6h, mm | - 17.79 ± 5.26 | - 11.44 ± 5.27 | 0.161 |
| nIAUC30min/9h, mm | - 18.08 ± 5.31 | - 10.93 ± 5.31 | 0.084 |
| nIAUC30min/22h, mm | - 17.45 ± 5.97 | - 9.72 ± 5.97 | 0.054 |
| nIAUC30min/28h, mm | - 17.33 ± 6.04 | - 9.43 ± 6.04 | 0.057 |
| nIAUC30min/32h, mm | - 17.45 ± 6.03 | - 10.193 ± 6.03 | 0.078 |
Results are presented by mean ± SE